2011
3rd International Adrenal Cancer Symposium
17-19 february 2011, Wurzburg, Germany
info >>
AAES Annual Meeting
10 - 12 April, 2011, Houston, TX, USA
info >>
ECE 2011
April 30th - May 4th, 2011, Rotterdam, The Netherlands
info >>
4th Workshop of ESES - 2011
Malignant Adrenal Tumours
12 – 14 May, 2011, Lyon, France
info >>
ENDO 2011
4 - 7 June, 2011, Boston, USA
info >>
2011 IAES MEETING
Held in Association with International Surgical Week, 44th World Congress of Surgery of ISS/SIC
August 28-September 1, 2011, Yokohama, Japan
info >>
Third International Symposium on Pheochromocytoma
14 - 17 september 2011, Paris, France
info >>
----------------------------------------------------------------------------------------
2010
Multiple Endocrine Neoplasia Workshop
16-18 september 2010, Gubbio, Italien
info >>
Report from MEN 2010 workshop
14th Congress of the ENEA
22-25 september 2010, Liège, Belgien
info >>
----------------------------------------------------------------------------------------
2009
Dopastatin - A new chimeric molecule for treatment of neuroendocrine tumors
On January 29, 2009 Ipsen Pharma organized a Scandinavian meeting at Arlanda Airport for endocrinologists, gastroenterologists, oncologists and surgeons, to discuss neuroendocrine tumors. Professor Kjell Öberg was the chairman and presented an update on biological treatment of neuroendocrine tumors. At that meeting Dopastatin was presented by Michael Culler from Beaufort Ipsen, as a new compound of interest both for neuroendocrine tumors and also for other endocrine tumors.
On February 2, 2009 Ipsen Pharma organized an Advisory Board in Paris where Professor Kjell Öberg is a member, to discuss the development of Dopastatin for treatment of NETs and also decide upon a clinical Phase II trial which will commence at the beginning of the autumn this year. It will be performed in patients with classical midgut carcinoid. In patients that has not been treated with either somatostatin analogs or dopamine agonists. Dopastatin is a new chimeric molecule that binds both to somatostatin receptor type 2 and dopamine receptor 2. It is known that classical midgut carcinoid tumors express both these receptors and therefore this chimeric molecule might have an impact on the treatment of these tumors.
NCI sponsored neuroendocrine tumor pathology summit, February 7-8, 2009 in Miami
It has been recognized that the classification of neuroendocrine tumors is not clear world-wide. The European Neuroendocrine Tumor Society (ENETS) has developed a classification system, based on the WHO-classification including TNM, staging and a grading system. This classification is different from the American system, just including a different grading system. Another difference is that in Europe proliferation capacity of the tumor is indicated by the pathologist as a percentage of dividing cells (Ki-67 positivity), but is seldom done in US. The impact of the European classification system is to try to tailor treatment for patients based on tumor biology. In this summit clinicians and pathologists from Europe and US met in Miami for a two-day meeting, discussing how we should reach a consensus with regard to classification of the tumors and what data should the pathology report include. The meeting was organized by Professor David Klimstra at Sloan Kettering Hospital, New York, and Professor Irvin Modlin, Yale University, New Haven. Representatives from Europe were Professor Kjell Öberg, Professor Guido Rindi from Parma, Professor Bertram Wiedenmann from Berlin and Professor Dermot O’Toole from Dublin
The European Neuroendocrine Tumor Society annual meeting
ENETS annual meeting is this year located to Granada, March 5-7. The meeting is the largest meeting in the field of neuroendocrine tumors and this year it is hosting 1200 participants. It has been growing every year. There are three invited speakers from the Centre of Excellence Endocrine Tumors, University Hospital, Uppsala, namely Professor Barbro Eriksson, Professor Göran Åkerström and Professor Kjell Öberg. See enclosed programme. Besides that Novartis is sponsoring a Satellite Symposium on Friday the 6th of March entitled “Evolving perspectives on the antiproliferative effects of octreotide treatment” with Professor Kjell Öberg as chairman and also speaker.
Program
Ipsen Nordic Knowledge Exchange Program, 13-17 April, 2009.
Tuesday 14 April, Uppsala.
Program
Basic Cource in NET's
25-27 May, 2009, in Uppsala
With participants from Russia, Middle East and South America.
2008
Professor Kjell Öberg and Dr Dan Granberg were invited to give presentations at Canadian Carcinoid Neuroendocrine Tumor Society (CNETS) October 16-19 2008, in Toronto. Professor Kjell Öberg gave two lectures at the British Columbia Cancer Center on October 20-21 in Vancouver, Canada.
Professor Kjell Öberg is invited to participate in the ESMO Conference entitled “Rare Tumors in Europe – Challengers and Solutions” on November 6 in Bruxelles.
Professor Kjell Öberg together with Professor Barbro Eriksson and Professor Göran Åkerström are invited to ENETS Advisory Board Conference, Palma de Mallorca, Spain, November 6-8, 2008.
Professor Kjell Öberg is organizing the Advanced Course in Neuroendocrine Tumors in Uppsala, November 17-19, 2008, with 40 participants from several countries world wide.
Professor Kjell Öberg is invited as a lecturer to First Master Class in Neuroendocrine Tumors, November 21-22 in Marrakech.
Professor Kjell Öberg is invited as a speaker at the ESMO Course Essentials of Medical Oncology in Istanbul, November 26-30, 2008.